Pharmacotherapy options: A) Rate control; B) Rhythm control.
A) DRUG | USUAL DOSE | ADVANTAGES | DISADVANTAGES | COST/30 D |
---|---|---|---|---|
β-blockers (β-1 cardioselective) | ||||
|
|
|
|
|
|
|
|
| |
Nondihydropyridine CCBs | ||||
|
|
|
|
|
|
|
| ||
Other | ||||
| 0.0625-0.25 mg OD |
|
| $15 |
B) DRUG | USUAL DOSE | ADVANTAGES | DISADVANTAGES | COST/30 D |
---|---|---|---|---|
Class III antiarrhythmics | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Class I antiarrhythmics | ||||
|
|
|
|
|
|
|
|
|
AF–atrial fibrillation, AV–atrioventricular, BID–twice daily, CAD–coronary artery disease, CCB–calcium channel blocker, CD–controlled delivery, CDR–Common Drug Review, CI–contraindicated, COPD–chronic obstructive pulmonary disease, CrCl–creatinine clearance, CV–cardiovascular, HF–heart failure, HR–heart rate, LV–left ventricular, LVEF–left ventricular ejection fraction, MI–myocardial infarction, OD–once daily, SR–sustained release, TID–3 times daily, XC–extended release. Data from Gillis et al1 and Jin and Kosar4